The global orthobiologics market is set to grow from USD 6.0 billion in 2023 to USD 8.1 billion by 2033, expanding at a compound annual growth rate (CAGR) of 3.0% during the forecast period.
Orthobiologics are biological materials used to accelerate healing in orthopedic conditions, including fractures, soft tissue injuries, and degenerative joint disorders. The market’s steady growth is driven by the increasing prevalence of musculoskeletal conditions, advancements in regenerative medicine, and rising demand for minimally invasive procedures.
Key products such as bone graft substitutes, growth factors, and stem cell therapies are gaining traction due to their effectiveness in enhancing recovery and improving patient outcomes. Additionally, ongoing research and development in biomaterials and cell-based therapies are expected to further boost market expansion.
A Comprehensive Full Report – https://www.futuremarketinsights.com/reports/orthobiologics-market
Key Takeaways:
- Market Growth: Valuation to grow from $6.0 billion in 2023 to $8.1 billion by 2033 at a CAGR of 3.0%.
- Driving Factors: Rising cases of orthopedic injuries, advancements in regenerative medicine, and growing adoption of minimally invasive procedures.
- Key Products: Bone graft substitutes, growth factors, and stem cell therapies are leading the market.
- Future Trends: Innovations in biomaterials and regenerative therapies to support continued growth.
The orthobiologics market’s growth underscores its vital role in enhancing patient recovery and advancing orthopedic treatment outcomes globally.
Growth Drivers
- Increasing Incidence of Bone Disorders: The rising prevalence of orthopedic conditions, including osteoarthritis and degenerative bone diseases, is driving demand for orthobiologics.
- Advancements in Medical Technology: Innovations in treatment methods and products, such as stem cell therapy and platelet-rich plasma (PRP) treatments, are enhancing the effectiveness of orthobiologics.
- Preference for Minimally Invasive Procedures: There is a growing trend towards less invasive surgical options, which often incorporate orthobiologics to promote healing and recovery.
- Rising Geriatric Population: An aging population that is more susceptible to musculoskeletal disorders is contributing to increased demand for orthobiologic treatments.
- Healthcare Investments: Increased healthcare spending and investments in advanced medical technologies are facilitating the adoption of orthobiologics in clinical settings.
Competition Scenario
The market players are focusing on creating advanced products that provide ease to patients. The research and development programs that deliver products to support the patient in their overall recovery process are another factor competitors focus on. This involves the integration of regenerative medicine, alternative therapies, and bone support products.
Latest Developments:
- Medtronic extends the product list with balloon kyphoplasty, tumor management, vertebroplasty, sports surgery, nucleus removal tools, and SpineLine reimbursement. These extensions are helping the hospital facilities along with the introduction of electrosurgical products.
- In 2023, Zimmer Biomet acquired embody, an orthobiologics company for US$ 155 million. The company focuses on soft tissue healing and enhanced pipeline area. The acquisition will enhance the supply chain and distribution channel.
Key Contributors of the Orthobiologics Market are
- Medtronic (Ireland)
- Zimmer Biomet
- DePuy Synthes (Johnson & Johnson Services, Inc.)
- Stryker
- Anika Therapeutics, Inc.
- SeaSpine
- Bioventus
- RTI Surgical
- MTF Biologics
- Arthrex, Inc.
- Smith & Nephew
Key Segments
By Product Type:
- Bone Growth Stimulators (BGS)
- Non-invasive Electrical BGS
- Invasive Electrical BGS
- Ultrasound BGS
- Viscosupplements
- Single Injection Viscosupplements
- Three Injection Viscosupplements
- Five Injection Viscosupplements
- Bone Graft Substitute
- Allografts
- Synthetics
- Xenografts
- Bone Morphogenetic Protein
By End User:
- Hospitals
- Ambulatory Surgical Centres
- Orthopaedics Clinics
By Region:
- North America
- Latin America
- Europe
- Asia Pacific (APAC)
- Middle East & Africa (MEA)
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
